188 related articles for article (PubMed ID: 17080765)
21. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
Taylor DJ; Grobler A; Abdool Karim SS
Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
[TBL] [Abstract][Full Text] [Related]
22. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
[TBL] [Abstract][Full Text] [Related]
23. A varying-stage adaptive phase II/III clinical trial design.
Dong G
Stat Med; 2014 Apr; 33(8):1272-87. PubMed ID: 24273128
[TBL] [Abstract][Full Text] [Related]
24. Group-sequential methods for adaptive seamless phase II/III clinical trials.
Stallard N
J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
[TBL] [Abstract][Full Text] [Related]
25. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.
Bretz F; Schmidli H; König F; Racine A; Maurer W
Biom J; 2006 Aug; 48(4):623-34. PubMed ID: 16972714
[TBL] [Abstract][Full Text] [Related]
26. Some thoughts on sample size: a Bayesian-frequentist hybrid approach.
Gordon Lan KK; Wittes JT
Clin Trials; 2012 Oct; 9(5):561-9. PubMed ID: 22865839
[TBL] [Abstract][Full Text] [Related]
27. Assessing the success probability of a Phase III clinical trial based on Phase II data.
Su Z
Contemp Clin Trials; 2010 Nov; 31(6):620-3. PubMed ID: 20713180
[TBL] [Abstract][Full Text] [Related]
28. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
29. Bayesian sample size determination for a Phase III clinical trial with diluted treatment effect.
Zhang YY; Ting N
J Biopharm Stat; 2018; 28(6):1119-1142. PubMed ID: 29513608
[TBL] [Abstract][Full Text] [Related]
30. A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development.
Chen C; Anderson K; Mehrotra DV; Rubin EH; Tse A
Contemp Clin Trials; 2018 Jan; 64():238-242. PubMed ID: 28966137
[TBL] [Abstract][Full Text] [Related]
31. Discounting phase 2 results when planning phase 3 clinical trials.
Kirby S; Burke J; Chuang-Stein C; Sin C
Pharm Stat; 2012; 11(5):373-85. PubMed ID: 22641524
[TBL] [Abstract][Full Text] [Related]
32. Joint probability of statistical success of multiple phase III trials.
Zhang J; Zhang JJ
Pharm Stat; 2013; 12(6):358-65. PubMed ID: 24106067
[TBL] [Abstract][Full Text] [Related]
33. [Surrogate endpoints].
Hill C
Bull Cancer; 1999; 86(7-8):622-4. PubMed ID: 10477379
[TBL] [Abstract][Full Text] [Related]
34. A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer.
Chen TT; Chute JP; Feigal E; Johnson BE; Simon R
J Natl Cancer Inst; 2000 Oct; 92(19):1601-7. PubMed ID: 11018096
[TBL] [Abstract][Full Text] [Related]
35. Meta-analysis of randomized phase II trials to inform subsequent phase III decisions.
Burke DL; Billingham LJ; Girling AJ; Riley RD
Trials; 2014 Sep; 15():346. PubMed ID: 25187348
[TBL] [Abstract][Full Text] [Related]
36. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
Chen YH; Li C; Lan KK
Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
[TBL] [Abstract][Full Text] [Related]
37. Design and analysis of clinical trials with a bivariate failure time endpoint, with application to AIDS Clinical Trials Group Study A5142.
DiRienzo AG; DeGruttola V
Control Clin Trials; 2003 Apr; 24(2):122-34. PubMed ID: 12689734
[TBL] [Abstract][Full Text] [Related]
38. Design, power, and alpha levels in randomized phase II oncology trials.
Haslam A; Olivier T; Prasad V
ESMO Open; 2023 Feb; 8(1):100779. PubMed ID: 36736072
[TBL] [Abstract][Full Text] [Related]
39. Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution.
Nickolich M; Babakoohi S; Fu P; Dowlati A
Clin Lung Cancer; 2014 May; 15(3):207-12. PubMed ID: 24485231
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
